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Cardiac phenotype of familial amyloid polyneuropthy according to
genotype
Vincent Algalarrondo [Orateur], Sylvie Dinanian, Christophe Juin, Sou-
miya Bennani, David Adams, Michel Slama
Hôpital A. Béclère, Cardiologie, Clamart, France
Introduction: Familial amyloid polyneuropathy (FAP) is an autosomic
dominant disease due to the mutation in the transthyretin gene. The abnormal
protein produced by the liver is responsible for polyneuropathy, autonomic
dysfunction and cardiac involvement. Myocardial hypertrophy and conduction
disturbances are the two major cardiac consequences in FAP. More than 100
mutations have been described: the substitution of methionine for valine at
position 30 (Val30Met mutation) is the most common.
Methods: The aim of our study was to compare cardiac data of the Val30Met
population to other FAP population. One hundred ninety four consecutive patients
(pts) were referred to our department to have a cardiac evaluation after FAP diag-
nosis,168 pts out of them were genotyped. Standard ECG, echocardiography and
electrophysiological study were performed for each patient.
Results: Main results are shown in table 1. In patients carrying other muta-
tions than Val30Met, cardiac hypertrophy was associated with a longer HV
interval (71±2ms in case of hypertrophy vs. 58±4ms ;P=0.0008). Such associ-
ation wasn’t found considering Val30Met patients.
Table 1: Main results
Abnormal ECG: RBB, LBB, abnormal axis or nodal AV block. Cardiac
hypertrophy: interventricular septum thickness >12 mm. LW: lucianni Wenck-
ebach anterior point.
Conclusions: Demographic data and cardiac phenotype are significantly
different according to the genotype between the val30met and other mutations
population. In pts carrying other mutation than Val30Met, cardiac hypertrophy
and infra nodal block were more common and seemed to be related. Follow
up and treatment must take into a count the genotype. 
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Ephrin-B1: a new ultrastructural protein 
of the cardiomyocyte
Céline Gales [Orateur], Gael Genet [Orateur], Benjamin Honton [Orateur],
Céline Guilbeau-Frugier, Fabien Despas, Marie-Françoise Altie, Atul
Pathak, Jean-Michel Senard
INSERM U858, Equipe 8 – Dpt Remodelage cardiaque/renal, Toulouse
Cedex 4, France
Background: Ephrin-B1 is a ligand from Eph/Ephrin family involved in
cell-cell interactions. If the role of ephrine molecules is well known in embry-
onic tissue, their expressions/functions in adult remain unclear.
Aim: The aim of the present work is to characterize the cardiac phenotype
of two-months old ephrin-B1 knockout mice.
Results: Western-blot analysis demonstrated specific expression of ephrin-
B1 in total heart protein extracts from WT mice that was lost in KO mice.
Further IF studies demonstrated broad expression of ephrin-B1 protein
throughout all heart compartments (right ventricle, septum, left ventricle) with
different cellular localizations (cardiomyocytes and micro/macrocirculation).
HE stained-paraffin-embedded heart sections from KO mice revealed loss of
organized cardiac tissue characterized by the presence of wavy cardiomyo-
cytes in the myocardium from septum and right/left ventricles. Modification of
cardiomyocytes’ morphology correlates with a loss of their apparent lateral
junctions and a significant reduction in cytoskeleton proteins (α-actinin/β-
actin levels), consistent with a reduced size of the mycoytes. Ultrastructural
analysis (electronic microscopy) revealed significant loss of electronic density
of Z-disks and a highly packed intercalated disk (ID) with no modifications in
the ID space, probably as a consequence of myocytes’ lateral junction’s loss.
Functional analysis of KO-mice with echocardiography revealed a significant
increase in systolic and diastolic diameters of the left ventricle. Consistent
with disruption of myocardial architecture, electrocardiograms demonstrated a
first degree AV block together with a significant reduction of heart frequency.
Conclusion: This is the first report providing evidence for the presence of
ephrin molecules in the adult heart tissue. This study using ephrin-B1 KO
mouse identified ephrin-B1 as a new ultrastructural protein of the cardiomyo-
cyte whose deletion leads to a dilated cardiomyopathy.
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tion against Ischemic-Reperfusion Injury by Alteration of the RISK/
GSK-3β Signaling
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Médecine, Angers, France – (3) Laboratoire de biochimie, CHU
d’Angers, Angers, France – (4) INSERM U771, CNRS UMR 6214, Uni-
versité Angers, Faculté de Médecine, Angers, France – (5) UPRES 3860,
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Background: Recent studies using healthy animals have demonstrated car-
dioprotective effects of erythropoietin (EPO) against ischemic-reperfusion injury
by up-regulation of the RISK pathway. Here, we sought to examine whether
EPO-induced cardioprotection and activation of cardioprotective signaling is
maintained in presence of type I diabetes mellitus or insulin resistance.
Methods: Isolated Langendorff-perfused hearts were obtained from 3
cohorts of Wistar rats: healthy adults; animals injected 4 weeks earlier with
streptozotocin (STZ) to induce diabetes and rats fed for 4 weeks with a high
fat diet (HFD) to induce insulin resistance. All hearts underwent 25min
ischemia, and within each cohort, were assigned to receive either 2h reperfu-
sion with no intervention or a single dose of EPO (1000 IU/kg) injected at the
onset of reperfusion.
Results: In hearts from healthy rats: i) EPO was cardioprotective: infarct
size was 14.36±0.60% vs 36.22±4.20% of the left ventricle (LV) in EPO-
treated vs untreated healthy rat hearts; p<0.05; ii) EPO-induced cardioprotec-
tion was associated with significant increases in phosphorylated forms of Akt,
ERK1/2 and their downstream target GSK-3β, at 30min of reperfusin. At
4 wks post-STZ injection, rats displayed: i) inhibition of EPO-induced cardio-
protection: infarct size was 32.05±2.38% vs 31.88±1.87% of the LV in EPO-
treated vs untreated diabetic rat hearts; ii) no up-regulation of PI3K/Akt,
ERK1/2 and GSK-3β signaling in response to EPO. In contrast, at 4 weeks
post-HFD, rats showed: i) cardioprotective effect of EPO: infarct size was
18.66±1.99% vs 34.62±3.41% of the LV in EPO-treated vs untreated HFD rat
hearts; p<0.05; ii) up-regulation in PI3K/Akt, ERK1/2 and GSK-3β signaling
in response to EPO, at 30min of reperfusion.
January 14th, Thursday 2010
 Mean age
(years)
Gender % 
of male
Abnormal 
ECG
%
Cardiac 
hypertrophy 
%
LW 
point 
(bpm)
HV 
interval 
(ms)
Val30Met 
n=13 42.5 53 47 40 128±3 59
Other 
mutations 
n=55
55.7 71 46 72 151±3 66
p 0.0001 0.04 NS 0.0002 <0.0001 0.002
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Conclusion: Alteration of cellular signaling upstream of GSK-3β is respon-
sible for the lack of EPO protective effect in STZ-induced diabetic hearts.
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AngiotensinII induced atrial remodelling is worsened in mice overex-
pressing aldosterone synthase in cardiomyocyte
Ludovic Bénard [Orateur] (1), Laure Champ-Rigot (2), Sophie Gomes (2),
Camille Rodroguez (1), Jane-Lise Samuel (1), Claude Delcayre (1), Paul
Milliez (1)
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The aim of this work was to check the hypothesis that increased cardiac
aldosterone level combined with arterial hypertension may enhance the delete-
rious effects at the heart level. Transgenic mice overexpressing Aldo Synthase
(AS) in cardiomyocytes and wild type (WT) littermates were submitted to
AngII-induced hypertension by osmotic pump (1mg/kg/day) during 3 or
8 weeks.
Results: 1) Physiological analysis indicated that the arterial pressure
increased similarly (+50 mmHg) in AngII-perfused groups whatever the geno-
type. At the ventricular level, the hypertrophy and the fibrosis (x3, p<0.05)
developed identically in the 2 AngII-groups (p<0.05 versus matched groups)
independently of the time. In contrast, at the level of the atria, 3 wk AngII per-
fusion significantly worsened the dilatation +46% for AS mice and +33% for
WT (p<0.05 versus matched groups) and fibrosis in AS mice (+20% AngII AS
versus AngII WT, p<0.05). In the 8 wk perfused groups, the atrial diameters
and the fibrosis were increased compared to 3 weeks. Besides, we noticed that
AngII increased more P wave duration in AS mice than in WT. Interestingly
Eplerenone treatment (50mg/kg/day) prevented all these changes.
2) The electrical changes led us to study the atrial expression of connexin
(Cx) 40 and 43. In AS mice at basal state, we found a 4-fold increase in func-
tional Cx43 when compared to WT whereas the functional levels of Cx40
were similar in both groups. In AngII-mice we found a decrease of functional
Cx40 (–50% and –40% in AS and WT mice, respectively) whereas functional
Cx43 increased by 30% whatever the genotype.
In conclusion, we show for the first time that both cardiac aldosterone and
AngII regulate the expression of Cx40 and 43 in mouse left atria. In addition
our results suggest that cardiac aldosterone worsened the deleterious effects of
AngII-induced hypertension on left atria, through increases in dilatation,
fibrosis and it increases conduction time.
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Non-invasive assessment of murine pulmonary arterial pressure: vali-
dation and application to models of pulmonary hypertension
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titute for Technology Assessment, Boston, Etats-Unis – (5) Massachusetts
General Hospital, Anesthesia Center for Critical Care Research, Depart-
ment of Anesthesia, Boston, Etats-Unis
Background: Genetically modified mice offer the unique opportunity to
gain insights into the pathophysiology of pulmonary arterial hypertension
(PAH). In mice, right heart catheterization is the only available technique to
measure right ventricular systolic pressure (RVSP). However, it is a terminal
procedure and does not allow serial follow-up. Our objective was to validate
a non-invasive technique to assess RVSP in mice.
Methods: Right ventricle catheterization and echocardiography were simul-
taneously performed in mice with pulmonary hypertension induced acutely by
infusion of a thromboxane analogue, U-46619 or chronically by lung-specific
over-expression of interleukin 6 (IL-6). In a subgroup of mice, echocardio-
graphy was performed using light anesthesia before catheterization. Pulsed-
Doppler of pulmonary artery flow was recorded in the parasternal short axis
view. Pulmonary acceleration time (PAT), and ejection time (ET) were mea-
sured.
Results: Infusion of U-46619 acutely increased RVSP, shortened PAT and
decreased PAT/ET. The pulmonary flow pattern changed from symmetric at
baseline to asymmetric at higher RVSPs. Transgenic IL-6 mice had high
RVSP measured by catheter (39±7 mmHg), short PAT (17±4 ms) and low
PAT/ET ratio (31±8%). The PAT correlated linearly with RVSP (r2=–0.67;
p<0.0001), as did PAT/ET (r2=–0.76, p<0.0001). Sensitivity and specificity for
detecting high RVSP (>32 mmHg) were 100% (7/7) and 86% (6/7), respec-
tively, for both indexes (cutoff values: PAT <21 ms and PAT/ET <39%).
PAT/ET measured during light anesthesia correlated with PAT/ET obtained
during invasive catheterization (r2=0.87, p<0.0001). Intra-observer and inter-
observer variability of PAT and PAT/ET were less than 6%.
Conclusion: Pulmonary artery systolic pressure can be estimated noninva-
sively in mice. Echocardiography allows to monitor acute changes of RVSP
and to detect pulmonary hypertension. This technique enables to follow PAH
evolution easily and repeatedly in mice.
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Cardiac β3-adrenoceptors as a new 
therapeutic target in dilated cardiomyopathy
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